XML 62 R51.htm IDEA: XBRL DOCUMENT
v3.22.1

Commitments and Contingencies - Additional Information (Detail) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | 36 Months Ended
--- | --- | --- | --- | ---
Sep. 30, 2022 | Mar. 31, 2022 | Dec. 31, 2020 | Mar. 31, 2022 | Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2024
Embolitech LLC [Member] |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Contingent payments upon achievement of regulatory milestones |  |  |  | $ 1,000,000.0 |  |  |  |
Installment payment beginning period |  |  |  | 2023 |  |  |  |
Installment payment ending period |  |  |  | 2024 |  |  |  |
CRO [Member] |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Contractual obligation remaining to be paid |  | $ 9,000,000 |  | $ 9,000,000 |  |  |  |
CRO [Member] | Minimum [Member] |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Gross contractual obligation |  | 37,000,000 |  | 37,000,000 |  |  |  |
CRO [Member] | Maximum [Member] |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Gross contractual obligation |  | 40,000,000 |  | 40,000,000 |  |  |  |
CRO [Member] | Maximum [Member] | CRO Pass-through Expenses [Member] |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Gross contractual obligation |  | 30,000,000 |  | $ 30,000,000 |  |  |  |
In-Process Research and Development [Member] | Embolitech LLC [Member] |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Payments to acquire in-process research and development |  | $ 500,000 | $ 1,000,000.0 |  | $ 1,000,000.0 |  | $ 5,000,000.0 |
Contingency period ending year |  |  |  | 2033 |  |  |  |
In-Process Research and Development [Member] | Embolitech LLC [Member] | Forecast [Member] |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Contractual obligation payable in fiscal 2022 through fiscal 2024 |  |  |  |  |  |  |  | $ 2,000,000.0
In-Process Research and Development [Member] | Medical Device [Member] |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Payments to acquire in-process research and development |  |  | $ 200,000 |  |  | $ 800,000 |  |
Contingency period ending year |  |  |  | 2022 |  |  |  |
In-Process Research and Development [Member] | Medical Device [Member] | Forecast [Member] |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Contingent payments upon achievement of regulatory milestones | $ 1,100,000 |  |  |  |  |  |  |

X
- Definition Asset acquisition contingency period ending year. + References No definition available. + Details
Name: | srdx_AssetAcquisitionContingencyPeriodEndingYear
Namespace Prefix: | srdx_
Data Type: | xbrli:gYearItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset acquisition contingent payments upon achievement of regulatory milestones. + References No definition available. + Details
Name: | srdx_AssetAcquisitionContingentPaymentsUponAchievementOfRegulatoryMilestones
Namespace Prefix: | srdx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Asset acquisition installment payment, beginning period. + References No definition available. + Details
Name: | srdx_AssetAcquisitionInstallmentPaymentBeginningPeriod
Namespace Prefix: | srdx_
Data Type: | xbrli:gYearItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset acquisition installment payment, ending period. + References No definition available. + Details
Name: | srdx_AssetAcquisitionInstallmentPaymentEndingPeriod
Namespace Prefix: | srdx_
Data Type: | xbrli:gYearItemType
Balance Type: | na
Period Type: | duration

X
- Definition Commitments and contingencies. + References No definition available. + Details
Name: | srdx_CommitmentsAndContingenciesLineItems
Namespace Prefix: | srdx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Gross amount of contractual obligation, including the portion of the obligation satisfied to date. + References No definition available. + Details
Name: | srdx_GrossContractualObligation
Namespace Prefix: | srdx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Future cash outflow to pay for purchases of fixed assets that have occurred. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586 + Details
Name: | us-gaap_CapitalExpendituresIncurredButNotYetPaid
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments. + References No definition available. + Details
Name: | us-gaap_ContractualObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=srdx_EmbolitechLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=srdx_ClinicalResearchOrganizationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=srdx_CROPassThroughExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=srdx_MedicalDeviceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |